Patient, disease, and transplant characteristics
| Demographics . | Median (range) . | Number (n) . | Percentage . |
|---|---|---|---|
| Total | 21 | 100 | |
| Age | 45 (21-72) | — | — |
| Patient sex | |||
| Female | — | 10 | 48 |
| Male | — | 11 | 52 |
| Donor age | 34 (21-66) | — | — |
| Donor sex | — | — | — |
| Female | — | 10 | 48 |
| Male | — | 11 | 52 |
| Patient donor sex | |||
| Male patient/female donor | — | 4 | 19 |
| Patient CMV serostatus | |||
| Positive | — | 15 | 71 |
| Cell source | |||
| BM | — | 10 | 48 |
| PBSCs | — | 11 | 52 |
| Donor type | |||
| Matched related | — | 7 | 33 |
| Matched unrelated | — | 12 | 57 |
| Mismatched related (haplo) | — | 2 | 10 |
| HLA type (A,B,C, DR1, and DQB1) | |||
| 5 of 10 | — | 2 | 10 |
| 9 of 10 | — | 2 | 10 |
| 10 of 10 | — | 17 | 80 |
| Conditioning intensity | |||
| RIC | — | 21 | 100 |
| Etiology HLH | |||
| ALPS | — | 1 | 4.8 |
| Acute myeloid leukemia | — | 1 | 4.8 |
| Blastic plasmacytoid dendritic cell neoplasm | — | 1 | 4.8 |
| Diffuse large B-cell lymphoma | — | 2 | 9.5 |
| EBV | — | 1 | 4.8 |
| Juvenile rheumatoid arthritis | — | 2 | 9.5 |
| MCTD/SLE | — | 1 | 4.8 |
| T-cell lymphoma | — | 1 | 4.8 |
| No trigger | — | 10 | 47.7 |
| Mutations | — | 10 | 47.6 |
| STXBP2 | — | 2 | — |
| Perforin | — | 6 | — |
| Lyst/MUNC | — | 1 | — |
| GATA-2 | — | 1 | — |
| Last alemtuzumab to transplant (n = 18), d | 26 (19-32) | — | — |
| Time of diagnosis to transplant, mo | 8 (3-17) | — | — |
| Demographics . | Median (range) . | Number (n) . | Percentage . |
|---|---|---|---|
| Total | 21 | 100 | |
| Age | 45 (21-72) | — | — |
| Patient sex | |||
| Female | — | 10 | 48 |
| Male | — | 11 | 52 |
| Donor age | 34 (21-66) | — | — |
| Donor sex | — | — | — |
| Female | — | 10 | 48 |
| Male | — | 11 | 52 |
| Patient donor sex | |||
| Male patient/female donor | — | 4 | 19 |
| Patient CMV serostatus | |||
| Positive | — | 15 | 71 |
| Cell source | |||
| BM | — | 10 | 48 |
| PBSCs | — | 11 | 52 |
| Donor type | |||
| Matched related | — | 7 | 33 |
| Matched unrelated | — | 12 | 57 |
| Mismatched related (haplo) | — | 2 | 10 |
| HLA type (A,B,C, DR1, and DQB1) | |||
| 5 of 10 | — | 2 | 10 |
| 9 of 10 | — | 2 | 10 |
| 10 of 10 | — | 17 | 80 |
| Conditioning intensity | |||
| RIC | — | 21 | 100 |
| Etiology HLH | |||
| ALPS | — | 1 | 4.8 |
| Acute myeloid leukemia | — | 1 | 4.8 |
| Blastic plasmacytoid dendritic cell neoplasm | — | 1 | 4.8 |
| Diffuse large B-cell lymphoma | — | 2 | 9.5 |
| EBV | — | 1 | 4.8 |
| Juvenile rheumatoid arthritis | — | 2 | 9.5 |
| MCTD/SLE | — | 1 | 4.8 |
| T-cell lymphoma | — | 1 | 4.8 |
| No trigger | — | 10 | 47.7 |
| Mutations | — | 10 | 47.6 |
| STXBP2 | — | 2 | — |
| Perforin | — | 6 | — |
| Lyst/MUNC | — | 1 | — |
| GATA-2 | — | 1 | — |
| Last alemtuzumab to transplant (n = 18), d | 26 (19-32) | — | — |
| Time of diagnosis to transplant, mo | 8 (3-17) | — | — |